JP MORGAN/CALL/VERTEX PHARMACEUTICALS/325/0.1/17.01.25

JP MORGAN/CALL/VERTEX PHARMACEUTICALS/325/0.1/17.01.25 Share Price

DE000JL07U13

Delayed Börse Stuttgart 12:18:10 30/05/2024 pm IST
12.12 ^EUR	-4.94%

1 month	+34.67%
3 months	+1.51%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/CALL/VERTEX PHARMACEUTICALS/325/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing	30/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	25/05	MT

More news

Quotes 5-day view

Date	Price	Change
30/24/30	12.12	-4.94%
29/24/29	12.75	-8.21%
28/24/28	13.89	+1.46%
27/24/27	13.69	+3.32%
24/24/24	13.25	+3.52%

Delayed Quote Börse Stuttgart

Last update May 30, 2024 at 12:18 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JL07U1
ISIN	DE000JL07U13
Date issued	12/04/2023
Strike	325 $
Maturity	17/01/2025 (228 Days)
Parity	10 : 1
Emission price	6.13 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	13.89 €
Lowest since issue	6.47 €
Delta	0.9x
Omega	2.930
Premium	4.31x
Gearing	3.27x
Moneyness	1.357
Difference Strike	-143 $
Difference Strike %	-44.01%
Spread	0.3 €
Spread %	2.38%
Theoretical value	12.46
Implied Volatility	38.53 %
Total Loss Probability	16.98 %
Intrinsic value	10.71
Present value	1.755
Break even	459.92 €
Theta	-0.06x
Vega	0.06x
Rho	0.15x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

455.3 USD

Average target price

463.5 USD

Spread / Average Target

+1.80%

Consensus